arrow
P

Peter R. Carroll

University of California San Francisco
H指数:149
被引数:10.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer

寡转移性前列腺癌管理中,联合或不联合激素疗法进行转移病灶定向放疗的实用性

2025-12-010
PRE
Multivitamin Use After Prostate Cancer Diagnosis Is Associated with Lower Risk of Recurrence: A Prospective Cohort Study from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE)

前列腺癌诊断后使用复合维生素与复发风险降低相关:一项来自前列腺癌战略性泌尿学研究(CaPSURE)的前瞻性队列研究

2025-05-060
PRE
Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry

主动监测前列腺癌是否已变得更安全?全球临床登记研究的经验教训

2024-07-010
OAAI
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage
2024-06-033
PRE
Effect of a Home-based Walking Intervention on Cardiopulmonary Fitness and Quality of Life Among Men with Prostate Cancer on Active Surveillance: The Active Surveillance Exercise Randomized Controlled Trial
2024-06-013
OA
Shed Trop2 drives prostate cancer progression and Trop2 is a novel tissue prognostic biomarker and a candidate urinary marker for prostate cancer
2024-03-220
PRE
First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Prostatectomy
2024-02-0113
OA
High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker
2024-01-044
OAAI
Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial
2023-12-018
PRE
Delphi consensus project on prostate-specific membrane antigen (PSMA)-targeted surgery-outcomes from an international multidisciplinary panel
2023-11-284
PRE